Cargando…

Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System

OBJECTIVE: To assess the 5-year contraceptive efficacy and safety of a levonorgestrel (LNG) 52-mg intrauterine system (IUS) from an ongoing 10-year phase 3 contraceptive trial. METHODS: Study investigators enrolled 1,751 nulliparous and parous females aged 16–45 years and desiring contraception to r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teal, Stephanie B., Turok, David K., Chen, Beatrice A., Kimble, Thomas, Olariu, Andrea I., Creinin, Mitchell D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Contents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319579/ https://www.ncbi.nlm.nih.gov/pubmed/30531565 http://dx.doi.org/10.1097/AOG.0000000000003034

Ejemplares similares

Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device
por: Creinin, Mitchell D., et al.
Publicado: (2023)

Pregnancy Risk by Frequency and Timing of Unprotected Intercourse Before Intrauterine Device Placement for Emergency Contraception
por: BakenRa, Abena, et al.
Publicado: (2021)

Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users
por: Spotnitz, Matthew E., et al.
Publicado: (2020)

Efficacy, Safety, and Tolerability of a New Low-Dose Copper and Nitinol Intrauterine Device: Phase 2 Data to 36 Months
por: Turok, David K., et al.
Publicado: (2020)

Five-year Contraceptive Use of 52-mg Levonorgestrel Releasing Intrauterine System in Young Women, Menstrual Patterns, and New Contraceptive Choice
por: de Oliveira, Elaine Cristina Fontes, et al.
Publicado: (2023)

Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity: A Randomized Controlled Trial
por: Edelman, Alison B., et al.
Publicado: (2022)

Consecutive Use of the 52 mg Levonorgestrel-releasing Intrauterine System: Variations in Bleeding Patterns
por: Wittmann, Barbara Zantut, et al.
Publicado: (2020)

Non-contraceptive applications of the levonorgestrel intrauterine system
por: Rodriguez, Maria Isabel, et al.
Publicado: (2010)

Role of the levonorgestrel intrauterine system in effective contraception
por: Attia, Abdelhamid M, et al.
Publicado: (2013)

Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use
por: Miranda, Laura, et al.
Publicado: (2021)

Is 2-dimensional transvaginal ultrasonography necessary 6 weeks after insertion of the levonorgestrel 52-mg intrauterine device?
por: van der Heijden, Patty A.H.H., et al.
Publicado: (2022)

Demographic, Reproductive, and Medical Risk Factors for Intrauterine Device Expulsion
por: Anthony, Mary S., et al.
Publicado: (2022)

Accessibility of Pharmacist-Prescribed Contraceptives in Utah
por: Magnusson, Brianna M., et al.
Publicado: (2021)

Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A()()
por: Rowe, Patrick, et al.
Publicado: (2016)

Intrauterine Vacuum-Induced Hemorrhage-Control Device for Rapid Treatment of Postpartum Hemorrhage
por: D’Alton, Mary E., et al.
Publicado: (2020)

The Levonorgestrel Intrauterine System: A Pragmatic View of an Excellent Contraceptive
por: Jacobstein, Roy, et al.
Publicado: (2015)

Contraindications to Hormonal Contraception Among Postpartum Women in Texas
por: Coleman-Minahan, Kate, et al.
Publicado: (2021)

Method of Hormonal Contraception and Protective Effects Against Ectopic Pregnancy
por: Kopp-Kallner, Helena, et al.
Publicado: (2022)

The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability
por: Beatty, Megan N, et al.
Publicado: (2009)

Medication Abortion With Pharmacist Dispensing of Mifepristone
por: Grossman, Daniel, et al.
Publicado: (2021)

Patterns in Contraceptive Use Among Women of Mexican Origin in the United States and in Mexico
por: Coleman-Minahan, Kate, et al.
Publicado: (2022)

Levonorgestrel-releasing intrauterine systems for long-acting contraception: current perspectives, safety, and patient counseling
por: Costescu, Dustin J
Publicado: (2016)

Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
por: Simon, James A., et al.
Publicado: (2019)

Effects of the Coronavirus Disease 2019 (COVID-19) Lockdown on the Use of Contraceptives and Ovulation Inductors in France
por: Roland, Noémie, et al.
Publicado: (2021)

Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system
por: Kailasam, Chandra, et al.
Publicado: (2008)

Corrigendum to “Rowe P et al. safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A” [Contraception 2016;93:498–506]
por: Rowe, Patrick, et al.
Publicado: (2016)

Cost‐effectiveness analysis of a low‐dose contraceptive levonorgestrel intrauterine system in Sweden
por: Henry, Nathaniel, et al.
Publicado: (2015)

Improving patient safety in haemodialysis
por: Bray, Benjamin D., et al.
Publicado: (2015)

Implementation of a quality and safety checklist for haemodialysis sessions
por: Marcelli, Daniele, et al.
Publicado: (2015)

Levonorgestrel-Releasing Intrauterine System as a Contraceptive Method in Nulliparous Women: A Systematic Review
por: Zgliczynska, Magdalena, et al.
Publicado: (2020)

Exploring the Role of Levonorgestrel Intrauterine System (LNG-IUS) as a Method of Emergency Contraception (EC)
por: Kumari, Snigdha, et al.
Publicado: (2022)

A Framework Proposal for Quality and Safety Measurement in Gynecologic Emergency Care
por: Fauconnier, Arnaud, et al.
Publicado: (2020)

High convection volume in online post-dilution haemodiafiltration: relevance, safety and costs
por: Mostovaya, Ira M., et al.
Publicado: (2015)

Long-term efficacy and safety of levonorgestrel-releasing intrauterine system as a maintenance treatment for endometriosis
por: Kim, Hye Yun, et al.
Publicado: (2022)

Chronic Urticaria Suspected to be Caused by a 13.5 mg Levonorgestrel Intrauterine Device (Skyla®)
por: Ganguli, Malika P, et al.
Publicado: (2023)

Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives
por: Benagiano, Giuseppe, et al.
Publicado: (2009)

Efficacy and Long-term Outcomes of Repeated Large Loop Excision of the Transformation Zone of the Cervix
por: van de Sande, Anna J. M., et al.
Publicado: (2022)

Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD
Publicado: (2013)

Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo
por: Cavrois, Marielle, et al.
Publicado: (2019)

Clinical Efficacy of Dienogest versus Levonorgestrel-Releasing Intrauterine System for Adenomyosis
por: Yang, Siyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8ruudqae59k612huch2ff4heea